Correspondence regarding “Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa”
Year: 2020
Type: letter
Abstract: Delamanid (Dlm) containing regimens to treat RR-TB are effective, but more data on Dlm use is needed. Dlm remains an important treatment option in programmatic settings with high rates of HIV co-infection and in persons with limited treatment options.https://bit.ly/3cVLeUq
Source: European Respiratory Journal
Institutions: Médecins Sans Frontières, Médecins Sans Frontières, Médecins Sans Frontières, Médecins Sans Frontières, Médecins Sans Frontières, South African Medical Research Council, City of Cape Town, Department of Health, University of Cape Town, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, Harvard University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3044571078
